Stem Cell Therapy Investment
What makes Q Therapeutics a smart investment opportunity? Here are a few factors to consider:
- Impressive new technology—Q-Cells™ have been shown to provide robust myelination in disease models involving demyelination.
- Strong, well-protected, world-wide intellectual property position—Q Therapeutics holds 16 issued patents with more currently pending. Patent protection extends until 2020, covering both the composition and use of Q-Cells as well as other cells of the central nervous system.
- Clear, rapid path to market—Q-Cells are produced using a patented process that should facilitate a faster, less-complicated path to market.
- Experienced management team and expert advisors—With decades of collective scientific, medical, business and legal experience, the Q Therapeutics team of executives and advisors are well qualified to turn the company's vision into a successful reality.
- Key partnerships—Q Therapeutics is working with leading universities and industry experts to demonstrate safety and efficacy for human use, to manufacture Q-Cells, and to conduct clinical trials. We plan to conduct our first clinical trial at Johns Hopkins University, the world's leading transverse myelitis center.
- Short- and long-term potential—Q Therapeutics is in an outstanding position to bring new breakthrough products to market quickly, and then use those products as a foundation to develop next-generation cellular and non-cellular treatments.
|
COMPANY 
